Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Rhea-AI Summary
Relief Therapeutics (RLFTY) has released its 2024 Annual Report, highlighting operational achievements and pipeline progress. The company's chairman, Dr. Raghuram Selvaraju, emphasized their strengthened financial position and commitment to treating rare diseases.
Key developments include advancement of two core pipeline products:
- RLF-OD032: A next-generation liquid sapropterin formulation for phenylketonuria
- RLF-TD011: A proprietary hypochlorous acid solution for epidermolysis bullosa
The company anticipates significant clinical and regulatory milestones in 2025 as they continue to focus on delivering treatments for unmet medical needs.
Positive
- Pipeline advancement of two key drug candidates
- Strengthened financial position reported
- Multiple clinical and regulatory milestones expected in 2025
Negative
- None.
GENEVA, SWITZERLAND / ACCESS Newswire / April 10, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its 2024 Annual Report and provided a corporate update.
In his annual letter to shareholders, Dr. Raghuram Selvaraju, chairman of the board of directors, emphasized the Company's operational achievements, pipeline momentum, and strengthened financial position. "This past year, we built a stronger foundation and made measurable progress in executing our plans as we advanced our core pipeline and optimized our commercial strategy, always guided by our commitment to delivering meaningful solutions for patients with unmet medical needs," said Dr. Selvaraju. "We are particularly excited by the continued progress of RLF-OD032, our next-generation liquid sapropterin formulation for phenylketonuria, and RLF-TD011, our proprietary hypochlorous acid solution for epidermolysis bullosa. We look forward to important clinical and regulatory milestones in 2025."
Relief's 2024 Annual Report, which includes pipeline and portfolio updates, corporate governance and compensation disclosures, and financial statements, is available on the Company's website .
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
What are the key pipeline products highlighted in Relief Therapeutics (RLFTY) 2024 annual report?
What major milestones does RLFTY expect in 2025?
What is the purpose of Relief Therapeutics' RLF-OD032 drug candidate?
What therapeutic area is Relief Therapeutics' RLF-TD011 targeting?
